#	Pagina
attuale pagina	/open-h2020/projects/217597/index.html

Opendata, web and dolomites

SeroStrat

The first blood test for the early detection and prognosis of Acute Myeloid Leukaemia

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

SeroStrat project word cloud

Explore the words cloud of the SeroStrat project. It provides you a very rough idea of what is the project "SeroStrat" about.

blood detected near spin tools aml cumulative recurrence 27 world gt leukaemia bone rate persons fatal monitored jobs detection acute permit routinely samples effectiveness rights prognostic succumb disease aggressive invasive prognosis unfavourable josep quantified clinics expensive diagnostic types cells accurately survival profits spanish death carreras prestigious 2024 accounts biopharma model easily cytometry treatment named business exclusive painfulness risks flow intermediate immediately lowest diagnosed ivd 65 remission signs enter patients aged nature risk 2015 25 biomarker create biotech blasts instead innovative founded fast clinical move myeloid groups marrow cheap discriminates 60 serostrat company vitro leukos western 22m off

Project "SeroStrat" data sheet

The following table provides information about the project.

Coordinator	LEUKOS BIOTECH SL Organization address address: CALLE MUNTANER 383 PLANTA 3 PUERTA 2 city: BARCELONA postcode: 8021 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Spain [ES]
Project website	http://www.leukosbiotech.com/investors/
Total cost	71˙429 €
EC max contribution	50˙000 € (70%)
Programme	1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
Code Call	H2020-SMEInst-2018-2020-1
Funding Scheme	SME-1
Starting year	2018
Duration (year-month-day)	from 2018-05-01 to 2018-09-30

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	LEUKOS BIOTECH SL LEUKOS BIOTECH SL Organization address address: CALLE MUNTANER 383 PLANTA 3 PUERTA 2 city: BARCELONA postcode: 8021 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ES (BARCELONA)	coordinator	50˙000.00

Map

Project objective

Acute myeloid leukaemia (AML) accounts for about 25% of all leukaemia in the Western world. Its overall survival rate for 5 years is the lowest of all types of leukaemia (27%): above 60% of AML patients will succumb to the disease. Currently, there is no method for early detection of AML. It is diagnosed based on the presence of blasts in bone marrow samples and must be treated immediately to avoid a near-future death. Due to this late detection, AML treatment is of low effectiveness.

The aggressive and often fatal nature of AML makes it a priority for developing early and fast diagnostic and prognostic tools. We have identified a new biomarker for the early detection and prognosis of AML. This biomarker is detected and quantified by our innovative In vitro Diagnostic Test (IVD), named Serostrat, via a fast, cheap and routinely clinical blood analysis. We own the exclusive exploitation rights of SeroStrat. SeroStrat specifically targets the AML biomarker in blood cells, discriminates between AML unfavourable risk patients and AML patients with intermediate risks; is low-invasive and painfulness (only requires a blood sample instead of bone marrow samples); is fast and non-expensive (it can be used routinely in clinics in blood samples analysis by Flow cytometry) and will permit risk groups (persons aged >65), AML new patients, and persons in remission to be monitored easily and accurately for signs of recurrence.

We are Leukos Biotech S.L. (Leukos), a Spanish spin-off company founded in 2015 from the prestigious Josep Carreras Leukaemia Research Institute. Our goal is to enter fully into the biopharma sector, which will allow us to move to a business model which will create 50 new jobs and cumulative profits about € 22M by 2024.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SEROSTRAT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SEROSTRAT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

COPI (2020)

Carbon Offset Plug-in

Project Tracworx (2019)

Tracworx is a data analytics tool that allows you to establish bottlenecks in your patient flow, while understanding your efficiencies and ultimately your true capacity.